First- and Second-Generation Antipsychotics for Children and Young Adults
Summary of Comparative Effectiveness Results (1 of 2)
The evidence from within-class comparisons of first-generation antipsychotics (FGAs) with each other for pediatric use is insufficient to permit conclusions about effect sizes and statistical significance.
In between-class comparisons of FGAs with second-generation antipsychotics (SGAs) for pediatric use:
- Olanzapine and risperidone are more effective than haloperidol for reducing autistic symptoms in pervasive developmental disorders. The strength of evidence for this finding is low.
- SGAs (clozapine, olanzapine, and risperidone) are more effective than haloperidol in treating schizophrenia, as assessed by clinical global impressions, but not by effects on positive and negative symptoms. The strength of evidence for this finding is low.
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.